Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Partnered Content
Ask the Analyst
RSS Feeds
Subscribe
Advertise
Contact Us
FAQs
Reports Store
UsernamePublicRestriction
Tags:
Biosimilars Regulation Canada

Celltrion And Teva Catch Up On Canadian Trastuzumab

  • News

Executive Summary

Celltrion and Teva have now received a Health Canada approval for their Herzuma trastuzumab biosimilar. However, notices of compliance have already been granted for rival biosimilars from Mylan and Pfizer.

You may also be interested in...



Asia Deal Watch: Rhizen Licenses Chinese Rights For PI3K Inhibitor To Curon

Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.

Mylan Prepares To Launch Canada's First Trastuzumab Within Weeks

By the end of June, Mylan expects to have launched in Canada the Ogivri trastuzumab 150mg and 440mg vials for which it has just received regulatory approval.

Teva Gets Canadian Rituximab Nod, But Barriers May Remain

Teva has obtained Health Canada clearance for biosimilar rituximab through an alliance with Celltrion. But the Israeli group is keeping quiet on launch plans as patent litigation continues.

Table

View full table

Related Content

Generics Bulletin
Generics Bulletin

Topics

Tags:
Biosimilars Regulation Canada
UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By